Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults

 Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults

Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults

Shots:

  • The approval is based on P-III IMpower133 study results assessing Tecentriq + carboplatin and etoposide vs carboplatin and etoposide monothx in 403 adults with chemotherapy-naïve ES-SCLC
  • P-III IMpower133 study results: mOS (12.3 mos. vs 10.3 mos.), mPFS (5.2 mos. vs 4.3 mos.) 30% reduction in death, OS @1 year (51.7% vs. 38.2%). The regimen is included as a preferred treatment for previously untreated ES-SCLC in the 2019 NCCN Clinical Practice Guidelines in Oncology for SCLC
  • Tecentriq (atezolizumab) is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptor and novel therapy approved in Canada for SCLC and is being evaluated in 12 P-III trials as monothx or in combination with other drugs

Click here to read full press release/ article | Ref: Roche | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post